Document is current
Any future updates will be listed below
-
Authors
Oertel, Wolfgang H. https://orcid.org/0000-0002-7582-8166
Janzen, Annette
Henrich, Martin T.
Geibl, Fanni F.
Sittig, Elisabeth
Meles, Sanne K.
Carli, Giulia
Leenders, Klaus
Booij, Jan
Surmeier, D. James https://orcid.org/0000-0002-6376-5225
Timmermann, Lars
Strupp, Michael https://orcid.org/0000-0002-9544-2279
-
Funding
Funding for this research was provided by:
ParkinsonFonds Deutschland,Germany Andre Leysen Ulran Foundation, Belgium Stichting ParkinsonFonds, The Netherlands
ParkinsonFonds Deutschland, Germany
Stichting ParkinsonFonds The Netherlands
JPB Foundation, USA
- License Information
-
More Information
Article History
Received: 28 February 2024
Accepted: 8 August 2024
First Online: 2 September 2024
Competing interests
: Wolfgang H. Oertel has received speaker’s honoria on educational symposia sponsored by Abbvie, the International Movement Disorders Society and Stada Pharma. He acts as a consultant for Lario Therapeutics and is a member of advisory boards with Intrabio and MODAG. He holds stock options with Intrabio related to this manuscript and stock options with MODAG unrelated to this work. The institution of W.H.O., not W.H.O personally received/s scientific grants from the German Research Foundation, the Michael J Fox Foundation and Rittal Foundation unrelated to the manuscript. Jan Booij is a consultant of GE Healthcare. The institution of J.B., not J.B. personally received research funding from GE Healthcare. Lars Timmermann has received speaker’s honoria on educational symposia sponsored by Abbvie, Boston Scientific, DIAPLAN, Neuraxpharm, Novartis, the International Movement Disorders Society und Teva. He has been a consultant for Boston Scientific. The institution of L.T., not L.T. personally received/s funding by Boston Scientific, the German Research Foundation, the German Ministry of Education and Research, the Otto-Loewi-Foundation and the Deutsche Parkinson Vereinigung. Neither L.T. nor any member of his family holds stocks, stock options, patents or financial interests in any of the above-mentioned companies or their competitors. Michael Strupp is Joint Chief Editor of the Journal of Neurology, Editor in Chief of Frontiers of Neuro-otology and Section Editor of F1000. He has received speaker’s honoraria on educational symposia sponsored by Abbott, Auris Medical, Biogen, Eisai, Grünenthal, GSK, Henning Pharma, Interacoustics, J&J, MSD, NeuroUpdate, Otometrics, Pierre-Fabre, TEVA, UCB, and Viatris. He acts as a consultant for Abbott, AurisMedical, Bulbitec, Heel, IntraBio, Sensorion and Vertify. He is an investor and share-holder of IntraBio. The institution of M.S., not M.S. personally received/s support for clinical studies from Decibel, USA, Cure within Reach, USA and Heel, Germany. He distributes “M-glasses” and “Positional vertigo App”. The remaining authors declare no competing interests.
